Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May;198(5):500.e1-7.
doi: 10.1016/j.ajog.2008.03.064.

The economic burden of noncervical human papillomavirus disease in the United States

Delphine Hu  1 , Sue Goldie
Affiliations
Review

The economic burden of noncervical human papillomavirus disease in the United States

Delphine Hu et al. Am J Obstet Gynecol. 2008 May.

Abstract

Objective: The purpose of this study was (1) to estimate the direct medical costs of 7 major noncervical human papillomavirus (HPV)-related conditions that include genital cancers, mouth and oropharyngeal cancers, anogenital warts, and juvenile-onset recurrent respiratory papillomatosis, and (2) to approximate the economic burden of noncervical HPV disease.

Study design: For each condition, we synthesized the best available secondary data to produce lifetime cost per case estimates, which were expressed in present value. Using an incidence-based approach, we then applied these costs to develop an aggregate measure of economic burden.

Results: The economic burden that was associated with noncervical HPV-6-, -11-, -16-, and -18-related conditions in the US population in the year 2003 approximates $418 million (range, $160 million to $1.6 billion).

Conclusion: The economic burden of noncervical HPV disease is substantial. Analyses that assess the value of investments in HPV prevention and control programs should take into account the costs and morbidity and mortality rates that are associated with these conditions.

PubMed Disclaimer

Comment in

References

    1. Division of STD Prevention, Centers for Disease Control and Prevention. Atlanta (GA): Department of Health and Human Services; 1999. Dec, Centers.for Disease Control and Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants' Meeting. Available at: http://www.cdc.gov/nchstp/dstd/Reports_Publications/HPVSupplement%20.pdf.
    1. Wiley DA, Mansongsong E. Human papillomavus: the burden of infection. Obstet Gynecol Surv. 2006;61:S3–S14. - PubMed
    1. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24:S11–S25. - PubMed
    1. Lacey CJ, Lowndes CM, Shah KV. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(Chapter 4):S35–S41. - PubMed
    1. Koutsky LA, Harper DM. Current findings from prophylactic HPV vaccine trials. Vaccine. 2006;24(Chapter 13):S114–S121. - PubMed

Publication types

MeSH terms

LinkOut - more resources